Skyrizi is the brand name for risankizumab-rzaa, a self-injectible IL-23 inhibitor approved to treat plaque psoriasis in adults, who are candidates for systemic therapy or phototherapy, as well as psoriatic arthritis and Crohn's disease.  Ilumya is the brand name for tildrakizumab-asmn, which a doctor must administer for the treatment of plaque psoriasis in adults, who are candidates for systemic therapy or phototherapy.